The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Morningstar brands and products Company Portfolio ...

Teva 2024 Results earnings conference call today at 8:00am ET, webcast and replay: https://events.q4inc.com/attendee/899170090 * NDA (New Drug Application): Formal ...

AUSTEDO Revenue: $1.7 billion, up 36%. AJOVY Revenue: Over $0.5 billion, up 18%. UZEDY Revenue: $117 million. Generics Business Revenue: Close to $9.5 billion, up 11%. API Business Growth ...

As you'll see, AUSTEDO had another great year, up 34%. UZEDY had a very strong year, beating its target of $100 million, at $117 million, and AJOVY grew at 18% and reached the $0.5 billion number.